Simmerafil

Simmerafil
Clinical data
Other names	TPN171
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-[3-(4,5-Diethyl-6-oxo-1H-pyrimidin-2-yl)-4-propoxyphenyl]-2-(4-methylpiperazin-1-yl)acetamide;
CAS Number	1229018-87-4 ;
PubChem CID	136197286 ;
Chemical and physical data
Formula	C24H35N5O3
Molar mass	441.576 g·mol−1

Last updated July 17, 2025

Simmerafil^[1] (TPN171H) is a selective PDE5 inhibitor ^[2] in development for the treatment of erectile dysfunction ^[3] and pulmonary hypertension.^[4]

References

↑ Odilov, Abdullajon; Liu, Yin; Hu, Tianwen; Jiang, Xiangrui; Suo, Jin; Tian, Guanghui; Yang, Feipu; Shen, Jingshan (19 November 2021). "Facile and Cost-Effective Route for the Synthesis of Simmerafil" . Organic Process Research & Development. 25 (11): 2432–2437. doi:10.1021/acs.oprd.1c00184. ISSN 1083-6160. S2CID 244619662.
↑ Qian, Hongjie; Chen, Qian; Liang, Liyu; Zou, Yang; Pu, Huahua; Xin, Liang; Song, Rong; Li, Tingting; Zhu, Huijuan; Wang, Yu; Tian, Guanghui; Shen, Jingshan; Jiang, Hualiang; Yu, Chen; Wang, Zhen; Jia, Jingying (2021). "A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects". Drug Design, Development and Therapy. 15: 2947–2959. doi: 10.2147/DDDT.S308610 . ISSN 1177-8881. PMC 8273902 . PMID 34262260.
↑ "Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction". www.clinicaltrials.gov. CTG Labs. 6 March 2023. Retrieved 9 November 2023.
↑ Zhao, Congke; Hu, Liqing; He, Xiangrong; Li, Lijun; Yin, Minghui; Tettey, Abraham Terkpertey; Wang, Yu; Shen, Jingshan; Tang, Siyuan; Wu, Chunhui; Li, Qianbin; Wang, Zhen; Li, Xiaohui (1 August 2022). "TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats" . Vascular Pharmacology. 145 107017. doi:10.1016/j.vph.2022.107017. ISSN 1537-1891. PMID 35680060. S2CID 249490064.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Odilov, Abdullajon; Liu, Yin; Hu, Tianwen; Jiang, Xiangrui; Suo, Jin; Tian, Guanghui; Yang, Feipu; Shen, Jingshan (19 November 2021). "Facile and Cost-Effective Route for the Synthesis of Simmerafil" . Organic Process Research & Development. 25 (11): 2432–2437. doi:10.1021/acs.oprd.1c00184. ISSN 1083-6160. S2CID 244619662.

[2] Qian, Hongjie; Chen, Qian; Liang, Liyu; Zou, Yang; Pu, Huahua; Xin, Liang; Song, Rong; Li, Tingting; Zhu, Huijuan; Wang, Yu; Tian, Guanghui; Shen, Jingshan; Jiang, Hualiang; Yu, Chen; Wang, Zhen; Jia, Jingying (2021). "A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects". Drug Design, Development and Therapy. 15: 2947–2959. doi: 10.2147/DDDT.S308610 . ISSN 1177-8881. PMC 8273902 . PMID 34262260.

[3] "Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction". www.clinicaltrials.gov. CTG Labs. 6 March 2023. Retrieved 9 November 2023.

[4] Zhao, Congke; Hu, Liqing; He, Xiangrong; Li, Lijun; Yin, Minghui; Tettey, Abraham Terkpertey; Wang, Yu; Shen, Jingshan; Tang, Siyuan; Wu, Chunhui; Li, Qianbin; Wang, Zhen; Li, Xiaohui (1 August 2022). "TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats" . Vascular Pharmacology. 145 107017. doi:10.1016/j.vph.2022.107017. ISSN 1537-1891. PMID 35680060. S2CID 249490064.

[1]

[2]

[3]

[4]